Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100

NCT05684705 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2025-01-14

No results posted yet for this study

Summary

Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100

Conditions

Interventions

DRUG

BV100

Intravenous infusion

Sponsors & Collaborators

  • CW-Research and Management GmbH

    collaborator UNKNOWN
  • BioVersys AG

    lead INDUSTRY

Principal Investigators

  • Lisa Husband, MD · BioVersys SAS

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-09-01
Primary Completion
2024-10-30
Completion
2024-12-30

Countries

  • Austria

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05684705 on ClinicalTrials.gov